A Phase 4 interventional study of Adefovir and Entecavir in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 9 sites in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-10.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing adefovir in Hepatitis B, Chronic — none open to participants now, none under way, none of them phase 3. adefovir · Hepatitis B, Chronic.
Among the 29 studies testing adefovir in Hepatitis B, Chronic, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2010, is one of 19 in phase 4, and was the 17th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 29 studies testing adefovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
adefovir: first FDA approval 2002 (HEPSERA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 280 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 164 across the 28 interventional studies. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2010, is one of 16 in phase 4, and was the 9th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing adefovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 3 arm study will assess the efficacy and safety of PEGASYS alone, or in combination with Adefovir or Entecavir in patients with HBeAg positive chronic hepatitis B. Patients will be randomized to receive 1)PEGASYS 180 micrograms sc weekly for 48 weeks + placebo from weeks -4 to 2;2)PEGASYS 180 micrograms sc weekly for 48 weeks + Adefovir from weeks -4 to 2; or 3)PEGASYS 180 micrograms sc weekly for 48 weeks + Entecavir from weeks -4 to 2. Treatment will be followed by 24 weeks of treatment-free follow-up.The anticipated time on study treatment is 1 year, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Adefovir · Drug: peginterferon alfa-2a [Pegasys]
Drug: Entecavir · Drug: peginterferon alfa-2a [Pegasys]
Drug: Placebo · Drug: peginterferon alfa-2a [Pegasys]
Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment
HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of hepatitis B e-antibody (anti-HBe/HBeAb) (a positive result for anti-HBe).
Time frame: Week 100
Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
HBV DNA (copies per milliliter \[copies/mL\]) represented the viral load for Hepatitis B Virus (HBV), and was considered an indicator of viral replication.
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Percentage of Participants Who Were HBeAg Negative
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels
The normal range for ALT is 10 to 40 international units per liter (IU/L).
Time frame: Baseline, Weeks 6, 12, 16, 22, 28, 34, 40, 46, 52, 64, 76, 88, and 100
Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
Percentage of Participants With Combined Response
Combined response was defined as having negative HBeAg, HBV DNA less than (\<) 100,000 copies/mL, and normal ALT level (10-40 IU/L).
Time frame: Baseline, Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
| Milestone | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Started | 91 | 95 | 94 |
| Completed | 85 | 88 | 90 |
| Not completed | 6 | 7 | 4 |
| Withdrew: Adverse event/intercurrent illness | 3 | 0 | 0 |
| Withdrew: Insufficient therapeutic response | 0 | 0 | 1 |
| Withdrew: Violation of selection criteria at entry | 0 | 1 | 0 |
| Withdrew: Refused treatment/did not cooperate | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 2 | 5 | 2 |
| Withdrew: Abnormality of laboratory test | 0 | 1 | 1 |
HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of hepatitis B e-antibody (anti-HBe/HBeAb) (a positive result for anti-HBe).
| percentage of participants | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment | 27.4 (17.8 to 36.9) | 29.5 (20.0 to 39.1) | 36.3 (26.4 to 46.1) |
HBV DNA (copies per milliliter \[copies/mL\]) represented the viral load for Hepatitis B Virus (HBV), and was considered an indicator of viral replication.
| copies/mL | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Baseline (n=91,95,94) | 8.65 ± 1.03 | 8.30 ± 1.21 | 8.41 ± 0.96 |
| Change at Week 4 (n=90,94,92) | -2.15 ± 0.94 | -2.76 ± 0.97 | -0.23 ± 0.88 |
| Change at Week 8 (n=90,94,92) | -1.87 ± 1.40 | -3.58 ± 1.12 | -1.32 ± 1.32 |
| Change at Week 16 (n=90,94,92) | -2.14 ± 1.72 | -3.77 ± 1.53 | -2.13 ± 1.93 |
| Change at Week 28 (n=90,94,92) | -2.34 ± 1.90 | -3.07 ± 1.88 | -2.84 ± 2.14 |
| Change at Week 40 (n=90,94,92) | -2.61 ± 2.11 | -2.97 ± 2.11 | -3.27 ± 2.25 |
| Change at Week 52 (n=90,94,92) | -2.75 ± 2.29 | -2.81 ± 2.43 | -3.32 ± 2.48 |
| Change at Week 64 (n=90,94,92) | -1.87 ± 2.26 | -1.37 ± 2.31 | -2.11 ± 2.42 |
| Change at Week 76 (n=90,94,92) | -1.91 ± 2.24 | -1.39 ± 2.46 | -2.20 ± 2.57 |
| Change at Week 88 (n=90,94,92) | -1.78 ± 2.36 | -1.39 ± 2.42 | -2.30 ± 2.34 |
| Change at Week 100 (n=90,94,92) | -2.00 ± 2.35 | -1.78 ± 2.41 | -2.17 ± 2.44 |
| percentage of participants | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Baseline (n=91,95,94) | 3.3 (0.0 to 7.0) | 2.1 (0.0 to 5.0) | 0.0 (NA to NA) |
| Week 4 (n=90,94,92) | 5.6 (0.8 to 10.3) | 4.3 (0.2 to 8.3) | 1.1 (0.0 to 3.2) |
| Week 8 (n=90,94,92) | 6.7 (1.5 to 11.8) | 6.4 (1.4 to 11.3) | 4.3 (0.2 to 8.5) |
| Week 16 (n=90,94,92) | 6.7 (1.5 to 11.8) | 8.5 (2.9 to 14.2) | 10.9 (4.5 to 17.2) |
| Week 28 (n=90,94,92) | 11.1 (4.6 to 17.6) | 10.6 (4.4 to 16.9) | 16.3 (8.8 to 23.9) |
| Week 40 (n=90,94,92) | 18.9 (10.8 to 27.0) | 18.1 (10.3 to 25.9) | 22.8 (14.2 to 31.4) |
| Week 52 (n=90,94,92) | 22.2 (13.6 to 30.8) | 22.3 (13.9 to 30.8) | 29.3 (20.0 to 38.7) |
| Week 64 (n=90,92,92) | 24.4 (15.6 to 33.3) | 25.0 (16.2 to 33.8) | 31.5 (22.0 to 41.0) |
| Week 76 (n=88,88,92) | 25.0 (16.0 to 34.0) | 28.4 (19.0 to 37.8) | 37.0 (27.1 to 46.8) |
| Week 88 (n=86,87,90) | 27.9 (18.4 to 37.4) | 27.6 (18.2 to 37.0) | 34.4 (24.6 to 44.3) |
| Week 100 (n=84,87,91) | 28.6 (18.9 to 38.2) | 32.2 (22.4 to 42.0) | 37.4 (27.4 to 47.3) |
| percentage of participants | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Baseline (n=91,95,94) | 0.0 | 0.0 | 0.0 |
| Week 4 (n=90,94,92) | 0.0 | 0.0 | 0.0 |
| Week 8 (n=90,94,92) | 0.0 | 0.0 | 0.0 |
| Week 16 (n=90,94,92) | 0.0 | 0.0 | 0.0 |
| Week 28 (n=90,94,92) | 0.0 | 0.0 | 0.0 |
| Week 40 (n=90,94,92) | 0.0 | 0.0 | 0.0 |
| Week 52 (n=90,94,92) | 0.0 | 0.0 | 0.0 |
| Week 64 (n=90,92,92) | 0.0 | 0.0 | 0.0 |
| Week 76 (n=88,88,92) | 0.0 | 0.0 | 0.0 |
| Week 88 (n=86,87,90) | 1.2 | 0.0 | 3.4 |
| Week 100 (n=84,87,91) | 0.0 | 0.0 | 0.0 |
The normal range for ALT is 10 to 40 international units per liter (IU/L).
| percentage of participants | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Baseline (n=91,95,94) | 4.4 | 3.2 | 2.1 |
| Week 6 (n=90,93,92) | 4.4 | 5.4 | 6.5 |
| Week 12 (n=90,93,92) | 15.6 | 17.2 | 13.0 |
| Week 16 (n=90,93,92) | 21.1 | 24.7 | 20.7 |
| Week 22 (n=90,93,92) | 25.6 | 34.4 | 22.8 |
| Week 28 (n=90,93,92) | 26.7 | 30.1 | 23.9 |
| Week 34 (n=90,93,92) | 26.7 | 34.4 | 32.6 |
| Week 40 (n=90,93,92) | 30.0 | 39.8 | 32.6 |
| Week 46 (n=90,93,92) | 30.0 | 41.9 | 33.7 |
| Week 52 (n=90,93,92) | 33.3 | 34.4 | 32.6 |
| Week 64 (n=90,92,92) | 32.2 | 37.0 | 42.4 |
| Week 76 (n=89,89,92) | 43.8 | 38.2 | 46.7 |
| Week 88 (n=86,88,91) | 32.6 | 33.0 | 48.4 |
| Week 100 (n=84,88,91) | 36.9 | 40.9 | 49.5 |
| International Units/milliliter (IU/mL) | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Baseline (n=91,95,94) | 3.97 ± 0.72 | 3.76 ± 0.83 | 3.84 ± 0.71 |
| Change at Week 4 (n=90,94,92) | -0.26 ± 0.48 | -0.18 ± 0.44 | -0.02 ± 0.33 |
| Change at Week 8 (n=90,94,92) | -0.33 ± 0.78 | -0.31 ± 0.58 | -0.25 ± 0.56 |
| Change at Week 16 (n=90,94,92) | -0.40 ± 0.78 | -0.49 ± 0.74 | -0.48 ± 0.83 |
| Change at Week 28 (n=90,94,92) | -0.61 ± 0.96 | -0.68 ± 0.98 | -0.70 ± 1.08 |
| Change at Week 40 (n=90,94,92) | -0.71 ± 1.09 | -0.67 ± 1.04 | -0.82 ± 1.27 |
| Change at Week 52 (n=90,94,92) | -0.78 ± 1.27 | -0.69 ± 1.11 | -0.88 ± 1.41 |
| Change at Week 64 (n=90,94,92) | -0.67 ± 1.18 | -0.54 ± 1.07 | -0.67 ± 1.21 |
| Change at Week 76 (n=90,94,92) | -0.58 ± 0.95 | -0.45 ± 1.01 | -0.53 ± 1.19 |
| Change at Week 88 (n=90,94,92) | -0.50 ± 1.11 | -0.44 ± 0.90 | -0.62 ± 1.20 |
| Change at Week 100 (n=90,94,92) | -0.41 ± 0.75 | -0.60 ± 1.15 | -0.56 ± 1.10 |
Combined response was defined as having negative HBeAg, HBV DNA less than (\<) 100,000 copies/mL, and normal ALT level (10-40 IU/L).
| percentage of participants | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| Baseline (n=91,95,94) | 0.0 | 0.0 | 0.0 |
| Week 16 (n=90,93,92) | 0.0 | 0.0 | 0.0 |
| Week 28 (n=90,93,92) | 0.0 | 1.1 | 0.0 |
| Week 40 (n=90,93,92) | 0.0 | 0.0 | 0.0 |
| Week 52 (n=90,93,92) | 0.0 | 0.0 | 0.0 |
| Week 64 (n=90,92,92) | 2.2 | 0.0 | 0.0 |
| Week 76 (n=88,89,92) | 3.4 | 0.0 | 0.0 |
| Week 88 (n=86,88,91) | 3.5 | 0.0 | 0.0 |
| Week 100 (n=84,88,91) | 2.4 | 0.0 | 0.0 |
Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peg-IFN-Alfa-2a + Adefovir | — | 7/91 (7.7%) | 85/91 (93.4%) |
| Peg-IFN-Alfa-2a + Entecavir | — | 12/94 (12.8%) | 83/94 (88.3%) |
| Peg-IFN-Alfa-2a + Placebo | — | 7/93 (7.5%) | 89/93 (95.7%) |
| Event | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 1/91 | 4/94 | 1/93 |
| Hepatitis BInfections and infestations | 2/91 | 0/94 | 0/93 |
| Hepatic failureHepatobiliary disorders | 1/91 | 0/94 | 0/93 |
| CellulitisInfections and infestations | 1/91 | 0/94 | 0/93 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/91 | 0/94 | 0/93 |
| Calculus urethralRenal and urinary disorders | 1/91 | 0/94 | 0/93 |
| Upper gastrointestinal heamorrhageGastrointestinal disorders | 1/91 | 0/94 | 0/93 |
| HepatitisHepatobiliary disorders | 0/91 | 1/94 | 1/93 |
| Peritonsillar abscessInfections and infestations | 0/91 | 0/94 | 1/93 |
| Urinary tract infectionInfections and infestations | 0/91 | 0/94 | 1/93 |
| Event | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo |
|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 23/91 | 27/94 | 25/93 |
| HeadacheNervous system disorders | 21/91 | 17/94 | 20/93 |
| PyrexiaGeneral disorders | 20/91 | 19/94 | 21/93 |
| Alanine aminotransferase increasedInvestigations | 14/91 | 17/94 | 18/93 |
| MyalgiaMusculoskeletal and connective tissue disorders | 17/91 | 13/94 | 18/93 |
| FatigueGeneral disorders | 13/91 | 12/94 | 15/93 |
| PruritisSkin and subcutaneous tissue disorders | 11/91 | 14/94 | 15/93 |
| DiarrhoeaGastrointestinal disorders | 14/91 | 9/94 | 13/93 |
| Upper respiratory tract infectionInfections and infestations | 6/91 | 11/94 | 14/93 |
| DizzinessNervous system disorders | 8/91 | 14/94 | 8/93 |
Intent-to-treat (ITT) analysis population included all randomized participants who received at least one dose of study medication.
| Age, Continuous(years) | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo | Total |
|---|---|---|---|---|
| Mean | 38.7 ± 9.7 | 37.7 ± 10.0 | 38.2 ± 9.7 | 38.2 ± 9.8 |
| Sex: Female, Male(Participants) | Peg-IFN-Alfa-2a + Adefovir | Peg-IFN-Alfa-2a + Entecavir | Peg-IFN-Alfa-2a + Placebo | Total |
|---|---|---|---|---|
| Female | 25 | 28 | 28 | 81 |
| Male | 66 | 67 | 66 | 199 |
Ran from May 2010 to primary completion in Sep 2014, 52 months.
Results were first posted in Nov 2015, 1 year 1 month after primary completion.
Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 52 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adefovir · Entecavir